Logo image of BCLI

BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Fundamental Analysis

USA - NASDAQ:BCLI - US10501E3009 - Common Stock

1.17 USD
-0.03 (-2.5%)
Last: 7/17/2025, 8:04:41 PM
0.67 USD
-0.5 (-42.74%)
After Hours: 7/17/2025, 8:04:41 PM
Fundamental Rating

1

BCLI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of BCLI have multiple concerns. BCLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCLI had negative earnings in the past year.
In the past year BCLI has reported a negative cash flow from operations.
BCLI had negative earnings in each of the past 5 years.
BCLI had a negative operating cash flow in each of the past 5 years.
BCLI Yearly Net Income VS EBIT VS OCF VS FCFBCLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

BCLI's Return On Assets of -310.45% is on the low side compared to the rest of the industry. BCLI is outperformed by 92.99% of its industry peers.
Industry RankSector Rank
ROA -310.45%
ROE N/A
ROIC N/A
ROA(3y)-443.44%
ROA(5y)-295.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCLI Yearly ROA, ROE, ROICBCLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K

1.3 Margins

BCLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCLI Yearly Profit, Operating, Gross MarginsBCLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for BCLI has been increased compared to 1 year ago.
The number of shares outstanding for BCLI has been reduced compared to 5 years ago.
BCLI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCLI Yearly Shares OutstandingBCLI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BCLI Yearly Total Debt VS Total AssetsBCLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -103.72, we must say that BCLI is in the distress zone and has some risk of bankruptcy.
BCLI has a worse Altman-Z score (-103.72) than 96.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -103.72
ROIC/WACCN/A
WACCN/A
BCLI Yearly LT Debt VS Equity VS FCFBCLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 0.21 indicates that BCLI may have some problems paying its short term obligations.
The Current ratio of BCLI (0.21) is worse than 94.96% of its industry peers.
A Quick Ratio of 0.21 indicates that BCLI may have some problems paying its short term obligations.
BCLI has a worse Quick ratio (0.21) than 94.78% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
BCLI Yearly Current Assets VS Current LiabilitesBCLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

BCLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BCLI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.08%
EPS Next 2Y25.71%
EPS Next 3Y18.1%
EPS Next 5Y22.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCLI Yearly Revenue VS EstimatesBCLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2028 2029 2030 2031 2032 100M 200M 300M
BCLI Yearly EPS VS EstimatesBCLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCLI. In the last year negative earnings were reported.
Also next year BCLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCLI Price Earnings VS Forward Price EarningsBCLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCLI Per share dataBCLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as BCLI's earnings are expected to grow with 18.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.71%
EPS Next 3Y18.1%

More info and screens

0

5. Dividend

5.1 Amount

BCLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (7/17/2025, 8:04:41 PM)

After market: 0.67 -0.5 (-42.74%)

1.17

-0.03 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12
Inst Owners12.89%
Inst Owner Change0%
Ins Owners12.88%
Ins Owner Change0%
Market Cap9.29M
Revenue(TTM)N/A
Net Income(TTM)-11.09M
Analysts82.86
Price Target15.47 (1222.22%)
Short Float %4.2%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.47%
Min EPS beat(2)-31.58%
Max EPS beat(2)54.52%
EPS beat(4)2
Avg EPS beat(4)5.98%
Min EPS beat(4)-31.58%
Max EPS beat(4)54.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.33%
PT rev (3m)21.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.07
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS-0.94
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -310.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-443.44%
ROA(5y)-295.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -103.72
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y33.08%
EPS Next 2Y25.71%
EPS Next 3Y18.1%
EPS Next 5Y22.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.53%
EBIT Next 3Y-9.08%
EBIT Next 5Y74.22%
FCF growth 1Y60.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.95%
OCF growth 3YN/A
OCF growth 5YN/A

BRAINSTORM CELL THERAPEUTICS / BCLI FAQ

What is the ChartMill fundamental rating of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BCLI.


What is the valuation status for BCLI stock?

ChartMill assigns a valuation rating of 0 / 10 to BRAINSTORM CELL THERAPEUTICS (BCLI). This can be considered as Overvalued.


What is the profitability of BCLI stock?

BRAINSTORM CELL THERAPEUTICS (BCLI) has a profitability rating of 0 / 10.


What is the financial health of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

The financial health rating of BRAINSTORM CELL THERAPEUTICS (BCLI) is 1 / 10.